Publisher： Adis International
ISSN： 1173-5503
Source： PharmacoEconomics and Outcomes News, Vol.1, Iss.318, 2001-01, pp. : 10-10
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content
Infliximab + methotrexate: the BeST induction therapy for early RA?
Inpharma, Vol. 1, Iss. 1547, 2006-01 ,pp. :
Access to resources
Recommend
TNF- inhibitors: `new era' of biological therapies for RA?
Inpharma, Vol. 1, Iss. 1267, 2000-01 ,pp. :
Is early intervention with biological agents worthwhile in RA?
Inpharma, Vol. 1, Iss. 1476, 2005-01 ,pp. :
Rofecoxib: an alternative to naproxen in juvenile RA?
Inpharma, Vol. 1, Iss. 1419, 2004-01 ,pp. :
Folate supplementation + methotrexate worthwhile in RA?
Inpharma, Vol. 1, Iss. 1447, 2004-01 ,pp. :